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Abstract In Europe, colorectal cancer is the most common
newly diagnosed cancer and the second most common
cause of cancer deaths, accounting for approximately
436,000 incident cases and 212,000 deaths in 2008. The
potential of high-quality screening to improve control of the
disease has been recognized by the Council of the European
Union who issued a recommendation on cancer screening
in 2003. Multidisciplinary, evidence-based European
Guidelines for quality assurance in colorectal cancer
screening and diagnosis have recently been developed by
experts in a pan-European project coordinated by the
International Agency for Research on Cancer. The full
guideline document consists of ten chapters and an
extensive evidence base. The content of the chapter dealing
with pathology in colorectal cancer screening and diagnosis
is presented here in order to promote international dis-
cussion and collaboration leading to improvements in
colorectal cancer screening and diagnosis by making the
principles and standards recommended in the new EU
Guidelines known to a wider scientific community.
Keywords Colorectal cancer screening.Multidisciplinary
evidence-based guidelines.Quality assurance.
Histopathology.Classification.Precursor lesions
Introduction
Colorectal cancer is a significant health problem, the
importance of which will increase substantially in the coming
years [1]. In Europe, colorectal cancer is the most common
newly diagnosed cancer and the second most common cause
of cancer deaths, accounting for approximately 436,000
incident cases and 212,000 deaths in 2008 [2]. Randomized
trials have shown that systematic screening of a target
population of suitable age can reduce colorectal cancer
(CRC) by detecting asymptomatic lesions [3–5]. Early
treatment is more effective and has a lower morbidity and
mortality. Moreover, the endoscopic removal of adenomas
reduces the incidence of CRC by stopping the progression of
precursor lesions to cancer. The potential of high-quality
screening to improve control of CRC has been recognized by
the Council of the European Union who issued a recom-
mendation on cancer screening in 2003 [6]. The recommen-
dation encourages the EU Member States to implement
population-based screening programmes using evidence-
based tests for breast, cervical and colorectal cancer,
according to European Quality Assurance Guidelines where
they exist. Comprehensive European Guidelines for quality
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prepared by experts and published by the European
Commission [7, 8]. Multidisciplinary, evidence-based Euro-
pean Guidelines for quality assurance in colorectal cancer
screening and diagnosis have recently been developed by
experts in a pan-European project coordinated by the
International Agency for Research on Cancer. The compre-
hensive guidelines cover the entire screening process
including clinical aspects, public health, organization and
communication. The full guideline document consists of ten
chapters and an extensive evidence base [9]. The content of
the chapter dealing with pathology in colorectal cancer
screening and diagnosis [10] is presented here in a slightly
modified format in order to promote international collabora-
tion in improvement of colorectal cancer screening and
diagnosis by making the principles and standards recom-
mended in the new EU Guidelines known to a wider
scientific community. This area is rapidly developing and
future evidence-based revisions will be required.
The pathology service plays a very important role in
colorectal cancer screening since the management of
participants in the programme depends on the quality and
accuracy of the diagnosis. Pathology affects the decision to
undergo further local and/or a major resection as well as
surveillance after screening. The adoption of formal
screening programmes leads to improvement not only in
the management of early but also advanced disease by the
introduction of guidelines, quality standards, external
quality assurance and audit. In screening programmes, the
performance of individuals and programmes must be
assessed and it is advantageous if common diagnostic
standards are developed to ensure quality, recognise areas
where sufficient evidence is still lacking, and initiate high-
quality studies to answer these questions. The present
chapter suggests practical guidelines for pathology within a
colorectal screening programme. We have concentrated on
the areas of clinical importance in the hope of standardising
these across the European Union. In the associated annex
[11], we deal with some of the more difficult areas and
suggest topics for future research. We have included
guidelines for the reporting and management of resected
specimens in an attempt to move towards agreed minimum
European standards of pathology in these areas as well.
This is the first edition of what will be a continuing process
of revision as new data emerge on the pathology, screening
and management of colorectal cancer. We hope to set
minimum standards that will be followed in all programmes
andtoencouragethedevelopmentofhigherstandardsamongst
the pathology community and screening programmes.
Manylesions arefoundwithinascreeningprogrammesome
of which are of little or no relevance to the aim of lowering the
burden of colorectal cancer in the population. The range of
pathology differs between the different approaches, with faecal
occultbloodprogrammes yieldinglater,moreadvanceddisease
than flexible sigmoidoscopy and colonoscopy screening.
Programme activities must focus on the identification and
appropriate management of invasive colorectal cancer and its
precursors. The management of pre-invasive lesions involves
surveillance to allow the prevention of future disease, whereas
management of adenocarcinoma focuses on immediate treat-
mentanddecisionsonlocalremoval,orradicalsurgerywiththe
potential for operative mortality. Overuse of radical surgery
must be avoided and recommendations for its use must be
balanced with the risks to the patient.
There are a number of lesions, especially in the serrated
pathway leading from hyperplastic polyps to other serrated
lesions and in some cases to adenocarcinoma, that may be
difficult to diagnose and for which knowledge of their natural
history and clinical implications is limited [12]. Further work
is required in this area, but until we understand these lesions
better it is recommended that all serrated lesions, with the
exception of hyperplastic polyps, be fully removed.
Few data were present in the literature on this issue. This
paucity of data is caused in part by a lack of standardisation
in terminology and limited observer agreement. Further-
more, a lack of prospective studies precludes a clear
indication of the optimal treatment and surveillance strategy
for lesions in the serrated pathway. For more information,
see Ref. [11]. The screening programme will also identify
other non-serrated neoplastic and non-neoplastic lesions
and provide important data on such conditions.
Methods
The process of evidence-based guideline development is
reported elsewhere in detail [13]. Briefly, scientific and
editorial management was performed by an editorial board
with experience in development of best practice guidelines,
in programme management and in evaluation of strategies
for CRC screening. The editorial board drafted an initial
comprehensive outline of the Guidelines and recruited a
multidisciplinary group of 50 experts across the European
Union to collaborate in revising the outline and drafting the
chapters according to an agreed methodology. An expert
Literature Group consisting of epidemiologists with special
expertise in the field of CRC and in critical appraisal of
clinical studies provided technical and scientific support to
the authors and editors in searching the relevant literature,
assessing the methodological quality of retrieved studies
and defining a grading system of the level of evidence and
strength of the recommendations.
The subgroup of authors responsible for the presently
reported chapter defined key clinical questions (modified
Patient-Intervention-Comparison-Outcome-Study method)
[14–16] for sensitive and specific bibliographic searches
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2000–2008; articles suggested by authors were also
considered. A study design hierarchy and inclusion/exclu-
sion criteria were developed for each type of question
(effectiveness, diagnostic accuracy, acceptability, etc.). The
methodological quality of the studies retrieved for the
clinical questions was assessed using validated checklists
for systematic reviews [17], randomized controlled trials
[18], observational studies [19] and diagnostic accuracy
studies [20]. Evidence tables and summary documents with
a synthesis of results and the level of evidence were
produced for each question by the literature group.
The subgroup of authors responsible for the presently
reported chapter received all the evidence tables and
summary documents relating to the formulated clinical
questions dealing with quality assurance in pathology of
CRC screening and diagnosis. The authors elaborated the
chapter draft describing the relevant issues and including
issues deemed to be relevant for a comprehensive multi-
disciplinary guideline, but not covered by the key clinical
questions. The authors summarized the available evidence,
and included recommendations and conclusions, as well as
a proposal for the strength of the evidence and the level of
each of the recommendations based on the evidence
collected by the literature group, their clinical experience,
and any additional relevant references collected by the
authors, including publications after December 2008. The
manuscript draft was repeatedly reviewed and revised in
workshops attended by the authors of all of the guideline
chapters as well as the editors and the literature group to
develop consensus on the final recommendations and
other content. A preliminary and a nearly final draft of
the present chapter was also reviewed and discussed in
multidisciplinary, pan-European meetings on colorectal
cancer screening conducted in 2008 and 2009 in which
experts from the 27 EU member states participated.
For each recommendation the strength of evidence was
indicated according to the following grading:
I. Multiplerandomizedcontrolledtrials(RCTs)ofreasonable
sample size, or systematic reviews (SRs) of RCTs
II. One RCT of reasonable sample size, or three or less
RCTs with small sample size
III. Prospective or retrospective cohort studies or SRs of
cohortstudies;diagnosticcross-sectionalaccuracystudies
IV. Retrospective case–control studies or SRs of case–
controls studies, time series analysis
V. Case series; before/after studies without control group,
cross-sectional surveys
VI. Expert opinion
If applicable, the lack of sufficient evidence to make a
recommendation was explicitly mentioned in the guideline
text. The consensus of the authors and editors on the
strength of a given recommendation was indicated according
to the following grading:
A. Intervention strongly recommended for all patients
B. Intervention recommended
C. Intervention to be considered but with uncertainty
about its impact
D. Intervention not recommended
E. Intervention strongly not recommended
Statementsofadvisorycharacterthattheauthorsconsidered
to be good practice but not of sufficient importance to warrant
formal grading were included in the chapter text.
In the final editing, the consistency and coherence of
recommendations was checked by the editorial board.
Strong recommendations, e.g. with grading A or E, but
with comparatively low levels of evidence, e.g. levels III–
VI, were accepted if an appropriate explanation was
provided by the authors.
Classification of lesions in the adenoma–carcinoma
sequence
A colorectal adenoma is defined as a lesion in the colon or
rectum containing unequivocal epithelial neoplasia. Classi-
fication of adenomas should include grading of neoplasia
according to the revised Vienna classification that has been
modified for the European Guidelines to obtain a two-tiered
system of low-grade and high-grade neoplasia (Table 1);
see also Ref. [21]. This modified grading system aims to
minimise intra- and inter-observer variation and facilitate
management of endoscopically detected lesions by improv-
ing correlation between histopathology of biopsies and
resection specimens [22]. Classically, adenomas are divided
into tubular, tubulo-villous or villous types and demarcation
between the three is based on the relative proportions of
tubular and villous components, according to the “20%
rule” described in the WHO classification of tumours in the
digestive tract [23]. At least 20% of the estimated volume
of an adenoma should be villous to be classified as a
tubulo-villous adenoma and 80% villous to be defined as a
villous adenoma. All other lesions are classified as tubular
[23] (VI-A). The reproducibility of villousness increases
when collapsing the categories into only two: tubular vs.
any villous component (i.e. anything >20% villous).
Adenomas can be endoscopically polypoid, flat or de-
pressed. Due to the increased risk of colorectal cancer
associated with flat and/or depressed lesions (III) they
should be reported as non-polypoid lesions (see: “Non-
polypoid adenomas”). The Paris endoscopic classification
of superficial neoplastic lesions should be used to describe
the gross appearance of colorectal adenomas (V-B). Key
features to report in a programme are size, villousness, the
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features suggesting the need for further intervention either
local or radical. The size of adenomas is important for their
risk of containing an adenocarcinoma but it is also related
to the need for subsequent surveillance, or colonoscopy.
The two-tiered grading of mucosal colorectal neoplasia
recommended in the European Guidelines (see Table 1)i s
based on the revised Vienna Classification that has improved
diagnostic reproducibility, particularly for non-polypoid
lesions [24–28] (IV-B). The recommended two-tiered grading
system also permits translation of histopathology findings of
Western and Japanese pathologists into a uniform system for
classification of colorectal neoplastic lesions.
In screening programmes the use of the term advanced
adenoma has developed and is sometimes used to categorise
adenomas for management. In this context an advanced
adenoma is one that is either ≥10 mm or contains high-grade
mucosal neoplasia or a villous component.
The hyperplastic polyp must be distinguished from other
serrated lesions due to its extremely low malignant potential.
The significance of other lesions in the serrated spectrum is
controversialandourknowledgeisstilldeveloping;traditional-
serrated adenomas and mixed polyps with neoplasia should be
considered as adenomas for the purpose of follow-up
(surveillance). More details are provided in Ref. [11].
Measurement of size of adenomas
Size (largest diameter) is an important objective measure-
ment best performed by the pathologist [29] from the slide,
as is recommended in the EU guidelines for breast cancer
screening [30]. Endoscopy measurements are less accurate
and should only be used when strictly necessary (III-B).
Pathology measurements are auditable, accurate, simple to
perform and able to assess the size of the adenomatous
component of mixed lesions. Although the quality of
evidence is low, there are some indications that different
modalities of advanced adenoma measurement (endoscopic
measurement vs. pathologist’s measurement before and
after fixation, on slide preparation) can affect diagnostic
reproducibility and the detection rate of advanced adeno-
mas. An overestimation or underestimation of a large or a
small polyp is important when the misjudgement crosses
the 10-mm threshold. It seems that the use of the
pathologist’s measurement is currently the most accurate.
If the lesion is too large for the maximum dimension to be
measured by this method, because it cannot be represented
on a single slide, the measurements taken at the time of
specimen dissection should be used. If a biopsy is received
or the specimen is fragmented it should be stated that it
cannot be accurately assessed for size by the pathologist
and the endoscopy measurements should be used. Measure-
ments should exclude the stalk if it is composed of normal
mucosa however the distance to the excision margin
should be noted. The size of adenomas is used to
determine the need for surveillance and therefore must
be measured accurately to the nearest millimetre (and not
rounded-up to the nearest 5 or 10 mm). Where the lesion
is mixed or only part of a lesion is adenomatous,
measurement should be performed on the adenomatous
component. Programmes should have a policy on the
methodology of, and should regularly monitor the
accuracy of size measurements of endoscopically re-
moved lesions. Deviation between the actual size and the
measurements of pathologists and endoscopists should be
minimised. Management decisions that depend on lesion
size should take into account potential inaccuracy in the
size measurement. The multidisciplinary team should
consider deviating from the recommended size categories
Table 1 Adaptation of the revised Vienna classification for colorectal
cancer screening
1. No neoplasia
a
Vienna category 1 (negative for neoplasia)
2. Mucosal low-grade neoplasia
Vienna category 3
Mucosal low-grade neoplasia
Low-grade adenoma
Low-grade dysplasia
Other common terminology
Mild and moderate dysplasia
WHO: low-grade intraepithelial neoplasia
3. Mucosal high-grade neoplasia
Vienna: category 4.1–4.4
Mucosal high-grade neoplasia
High-grade adenoma/dysplasia
Non-invasive carcinoma (carcinoma in situ)
Suspicious for invasive carcinoma
Intramucosal carcinoma
Other common terminology
Severe dysplasia
High-grade intraepithelial neoplasia
WHO: high-grade intraepithelial neoplasia
TNM: pTis
4. CARCINOMA invading the submucosa or beyond
4a. Carcinoma confined to submucosa
Vienna: category 5 (Submucosal invasion by carcinoma)
TNM: pT1
4b. Carcinoma beyond submucosa
TNM: pT2-T4
For revised Vienna classification, see Ref. [26]; for WHO classification,
see Ref. [23]; and for TNM, see [40–42]
aCategory2 ofthe Vienna Classification (indefinite)isnot recommended
for screening
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a case indicates that there is sufficient reason to doubt
the accuracy of the measurement. Such cases should be
captured as an auditable outcome (VI-B).
Tubular, tubulo-villous and villous adenomas: the typing
of villousness
The 20% rule only applies to wholly excised polyps and to
intact sections of lesions large enough to provide reliable
proportions. For small fragmented lesions or superficial polyp
biopsies, the presence of at least one clearly identifiable villus
meritsclassificationas“atleast tubulo-villous”. Definitionsof
the types of villousness are presented in Ref [11].
Non-polypoid adenomas
The role of the pathologist in the evaluation of non-
polypoid adenomas is to confirm the adenomatous nature of
the lesion, and to determine the grade of neoplasia as well
as the depth of depression in the case of a depressed non-
polypoid lesion (see below). Since the expression “flat
adenoma” is not well defined, it is recommended to group
together all adenomatous lesions other than polypoid into
the category of “non-polypoid adenomas” and avoid the
term “flat”. Non-polypoid adenomas correspond to an
endoscopical diagnosis of neoplasia in the subtypes IIa,
IIb and IIc according to the Paris classification. Completely
flat adenomas (type IIb) and depressed lesions (type IIc) are
rarely found in the colon and rectum, while slightly
elevated lesions (type IIa) are frequent. In the literature,
the height of non-polypoid adenomas has been described
histologically as not exceeding twice the height of normal
mucosa, thus measuring less than 3 mm in height. This
definition may be difficult to apply due to fixation artefacts
and in slightly depressed lesions since the adjacent mucosa
may be thinner than the normal epithelium. The endoscopic
diagnosis of a non-polypoid lesion should be reported
according to the Paris classification [21, 28, 31, 32] (III-B).
We were unable to retrieve studies that specifically address
the topic of the differences in the detection rates of non-
polypoid colorectal neoplasms among the different types of
screening programmes (FOBT vs. flexible sigmoidoscopy
vs. total colonoscopy), although a prevalence of 9–10% of
non-polypoid colorectal neoplasm (flat and depressed) was
recently reported by Western pathologists in a large cross-
sectional study [32]. Depressed lesions (type IIc) should be
mentioned in the histological report for clinico-pathological
correlation. Special care should be taken for centrally
depressed lesions, especially when the depression is deeper
than half of the adjacent lesion. These are reported to have
a higher frequency of high-grade neoplasia and invasion at
a smaller size than other flat or depressed lesions [21]. Non-
polypoid adenomas can show so-called lateral spread with
poor delineation of the margins thus making endoscopic
removal difficult.
Serrated lesions
Terminology
These lesions have in common a serrated morphology, but
depending on other characteristics, the potential to develop
into invasive adenocarcinoma differs considerably. Serrated
lesions vary from the hyperplastic polyp, which although
relatively common, has no implications for the screening
programme unless very numerous, proximally located or of
a large size (>10 mm), to sessile-serrated lesions (some-
times referred to as sessile-serrated polyps/sessile-serrated
adenomas), traditional-serrated adenomas,o rmixed
lesions/mixed polyps. Serrated lesions are infrequent, the
evidence base is poor and recommendations are not well
established, but until further evidence is forthcoming we
recommend the following:
Hyperplastic (metaplastic) polyp
Hyperplastic polyps are often small lesions (<5 mm in
diameter), frequently found in the left (distal) colon. They
are composed of simple elongated crypts with a serrated
structure in the upper half. These polyps usually show some
proliferation in the basal (non-serrated) part of the crypts
(regular proliferation). Nuclei are small, regular and basally
orientated. There is no hyperchromasia, and stratification of
the upper half of the crypts has a serrated appearance
without cytological atypia.
Hyperplastic polyposis should be excluded in cases with
giant hyperplastic polyps (>10 mm), or multiple hyperplastic
polyps in the right colon, or in first-degree relatives of
individuals with hyperplastic polyposis.
Sessile-serrated lesions
We recommend the use of the term sessile-serrated lesion
for serrated lesions with structural alterations that do not
show mucosal neoplasia. This term should replace the use
of sessile-serrated polyp and sessile-serrated adenomas until
better definitions are created.
1 It is not recommended to use
the latter terms in screening programmes because it would
1 The term sessile-serrated polyp has been proposed elsewhere for
serrated lesions that cannot be definitely classified into the category of
hyperplastic polyps or serrated adenomas [12], especially in cases
with technical inconsistencies such as tangential cuts or superficial
biopsies. The same terminology has been propsed for lesions with
minimal and focal structural alterations in the absence of cytological
atypia [86].
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practitioners.
Traditional-serrated adenomas
If the lesion shows a serrated morphology as well as
mucosal neoplasia (cytological abnormalities), it is consid-
ered to be a traditional-serrated adenoma (TSA) [33]. It
should be reported as such (TSA) and treatment and
surveillance should be the same as for adenomas. For
details see Ref. [11] as well as Chapter 9 of the EU
guidelines (Colonoscopic surveillance after adenoma re-
moval)[ 34]. This pragmatic recommendation recognises
the neoplastic nature of these lesions. The non-serrated
features found in such lesions (e.g. size and grade of
neoplasia) and any co-existing pathology (e.g. number of
neoplastic lesions) should be taken into account in selecting
an appropriate surveillance protocol (VI-C).
Mixed polyp
These are lesions with combinations of more than one
histopathologic type in the serrated spectrum (hyperplastic
polyps, sessile-serrated lesions, traditional-serrated adeno-
mas) or at least one type in combination with adenoma
[35]. The important feature to recognise for the screening
programme is the presence of neoplasia. The respective
types of lesion in a mixed polyp should be reported and the
term “mixed polyp” should only be used in brackets after
the diagnosis of the individual components (e.g. adenoma
and hyperplastic polyp, or traditional-serrated adenoma plus
adenoma). Mixed polyps should be completely removed. If
there is an adenomatous component, the lesion should be
followed up (surveillance) in the same manner as for
adenomas, taking into account the size and the grade of the
adenomatous component (VI-C).
Grading of neoplasia
The revised Vienna classification has been adopted here,
but in a simplified form suitable for screening and
diagnosis, by removing the indefinite category between
“negative for neoplasia” and “low-grade neoplasia”. This
category has no clinical value and unlike inflammatory
bowel disease is likely to be chosen very infrequently.
Excluding it reduces the number of categories and
simplifies the subsequent management choices. The advan-
tages of the revised Vienna Classification on which the
European screening classification is based are that it
improves diagnostic reproducibility [24, 26–28] (IV-B).
The modified format with a two-tiered grading of mucosal
colorectal neoplasia aims to further reduce inter-observer
variation [36] (IV-B). It encompasses the diagnostic
categories used in the Eastern and the Western schools
and each level has a clinical consequence. In the revised
Vienna classification, the term neoplasia is used which is
synonymous with the formerly used term “dysplasia”.I nt h e
two-tiered grading system recommended in the European
Guidelines, mucosal low-grade neoplasia corresponds to
neoplasiaofthesamegradeintherevisedViennaclassification;
mucosal high-grade neoplasia likewise corresponds to neopla-
sia of the same grade in the revised Vienna classification.
Invasive submucosal neoplasia in the European classification
corresponds to carcinoma invading the submucosa or beyond
in the Vienna classification (see Table 1).
Low-grade neoplasia
Low-grade neoplasia is an unequivocal neoplastic condition
confined to the epithelial glands. It should not be mistaken
for inflammatory or regenerative changes. Alterations
characteristic for low-grade neoplasia start from one gland
and develop into a microadenoma that then grows to
become macroscopically visible. Caution should be exer-
cised in patients with chronic inflammatory bowel disease
where the diagnosis of a neoplastic sporadic adenoma has
implications different from that of neoplasia in colitic
mucosa.
High-grade neoplasia
The changes of high-grade neoplasia should involve more
than just one or two glands (except in tiny biopsies of
polyps), and should therefore be identifiable at low-power
examination. Caution should be exercised in over-
interpreting isolated surface changes that may be due to
trauma, erosion or prolapse.
High-grade neoplasia is diagnosed on structure, supple-
mented by an appropriate cytology. Hence, its presence is
nearly always suspected by the low-power appearances where
complex structural abnormalities are present in structures
whose epithelium looks thick, blue, disorganised and with
focal cell debris and necrosis.
2 The structural features are:
& Complex glandular crowding and irregularity (note that
the word “complex” is important and excludes simple
crowding of regular tubules that might result from
crushing);
& Prominent glandular budding;
& A cribriform appearance and “back to back” glands; and
& Prominent intraluminal papillary tufting.
2 High-grade neoplasia also contains the subgroup of intramucosal
carcinoma used by some pathologists but not recommended here. For
details see Ref. [11].
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neoplasia, individually they are neither necessary nor
usually sufficient. Indeed they may occasionally occur in
lower grades of neoplasia, and that is why it is necessary to
further scrutinise the cytological features for signs of high-
grade neoplasia. The cytological features of high-grade
neoplasia are:
& Loss of cell polarity or nuclear stratification. High-grade
neoplasia should show at least 2–5 nuclear rows and
preferably a variable number of rows within individual
glands. The nuclei are haphazardly distributed within all
three thirds of the height of the epithelium. No maturation
of the epithelium is seen towards the luminal surface;
& Neoplastic goblet cells (retronuclear/dystrophic goblet
cells);
& Cytology includes vesicular or/and irregular round nuclei
with loss of polarity whereas spindle-like palisading
nuclei are a sign of low-grade intraepithelial neoplasia;
& Markedly enlarged nuclei, often with a dispersed
chromatin pattern and a prominent nucleolus;
& Atypical mitotic figures; and
& Prominent apoptosis, focal cell debris and necrosis.
Again, these features usually coexist in high-grade
neoplasia, and caution must be exercised in using just
one. It should be emphasised again that they should occur
in a background of complex structural abnormality. Marked
loss of polarity and nuclear stratification sometimes occurs
on the surface of small, structurally regular, tubular
adenomas that otherwise have a lower grade of neoplasia,
probably as a result of trauma, and must not be used to
classify a lesion as high grade. The only exception to the
rule is when the specimen consists of just a small biopsy
from a polyp, when there is insufficient tissue to assess the
architecture properly. In this situation it is permissible to
label florid cytological abnormalities alone as high-grade
neoplasia, but this will usually lead to re-excision of the
whole polyp, when it will be possible to assess the whole
lesion properly.
Also included within high-grade neoplasia is the
presence of definite invasion into the lamina propria of
the mucosa but not invasion through the mucscularis
mucosae.
Other lesions
Inflammatory polyps
Experience from UK pilot sites has shown that
inflammatory-type polyps are relatively common. Whilst
they are most usually seen as a complication of chronic
inflammatory bowel disease, particularly ulcerative colitis,
they are also seen in association with diverticulosis,
mucosal prolapse and at the site of ureterosigmoidostomy.
Furthermore, sporadic, single inflammatory-type polyps
(inflammatory cap polyp, cloacogenic inflammatory polyp,
myoglandular polyp, granulation tissue polyp etc.) are well
described in the colorectum. As the reporting pathologist
may not know the true context of such polyps, we
recommend that all such polyps be classified as “post
inflammatory polyp”. The term inflammatory pseudopolyp
(or even just “pseudopolyp”) should be avoided. Biopsies
with mucosal prolapse syndrome should be identified and
reported as such and not as neoplastic conditions.
Juvenile polyps
Juvenile polyps are spherical in shape, show an excess of
lamina propria, and have cystically dilated glands. The
expanded lamina propria shows oedema and mixed inflam-
matory cells. Experience from the UK faecal occult blood
pilot sites suggests that occasional juvenile-type polyps are
identified, even in the screening age group [37]. Juvenile
polyps are most common in children but occasional
examples are seen in adults. We advise that any polyp
showing juvenile polyp-type features should be classified
as “juvenile polyp” for the purposes of diagnostic reporting
in a screening programme. Juvenile polyps often show
epithelial hyperplasia but neoplasia is very rare. Single
sporadic juvenile polyps have a smooth surface, can be
found in all age groups and often are eroded. So-called
atypical juvenile polyps show different morphological
features, with a multilobated architecture, intact surface
mucosa and (usually) a much more pronounced epithelial
component. They are a characteristic feature of juvenile
polyposis.
Peutz–Jeghers polyps
Whilst these polyps are usually seen in the Peutz–Jeghers
syndrome, occasional examples are demonstrated as single,
sporadic polyps in the colon. There remains uncertainty as
to whether “inflammatory myoglandular polyp” represents
a similar entity. As with juvenile polyposis, it would seem
most unlikely, given the rarity of the syndrome and the age
of the screening population, that Peutz–Jeghers syndrome
would be diagnosed as part of a screening programme.
Although Peutz–Jeghers polyps are classified as hamarto-
mas, they have a very organised structure. They have a
central core of smooth muscle with conspicuous branching,
each branch being covered by colorectal-type mucosa that
appears hyperplastic but not neoplastic. As with sporadic
juvenile polyps, solitary Peutz–Jeghers-type polyps are
most unlikely to demonstrate foci of neoplasia.
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This condition is characterised by one or more of the
following conditions [38]:
& At least five histologically diagnosed serrated polyps
proximal to the sigmoid colon, of which two are >10 mm;
& Any number of serrated polyps occurring proximal to
the sigmoid colon in an individual who has a first-
degree relative with hyperplastic polyposis; and/or
& More than 30 serrated polyps of any size, but
distributed throughout the colon.
As mentioned above (see: “Hyperplastic (metaplastic)
polyp”), hyperplastic polyposis should be excluded in cases
with giant hyperplastic polyps (>10 mm, hyperplastic
polyps in the right colon or in first-degree relatives of
individuals with hyperplastic polyposis).
Cronkhite–Canada syndrome
We believe it is most unlikely that such cases will present
via a screening programme and the true diagnosis may not
be recognised by pathological assessment. However, if
Cronkhite–Canada syndrome is suspected, the pathologist
should contact the endoscopist and ask for clinical details to
ensure the diagnosis.
Neuroendocrine tumour
It is recommended to use the term “neuroendocrine
tumour” rather than carcinoid in accordance with the
WHO classification. These lesions are usually benign,
small lesions and do not give rise to diagnostic difficulty.
Colorectal intramucosal tumours with epithelial entrapment
and surface serration
Entrapment and pseudoinvasion of glands intothesubmucosal
layer must be distinguished from invasive carcinoma. If in
doubt, the relevant findings should be stated in the written
report. If evaluation is problematic, step sections, a second
opinion and further biopsies from the polypectomy ulcer
should be considered.
Non epithelial polyps
& Lipoma
& Leiomyoma of the muscularis mucosae
& Ganglioneuroma
& Gastrointestinal schwannoma
& Neurofibroma
& GIST
& Various forms of vascular tumour
& Perineurioma
& Fibroblastic polyp
& Epithelioid nerve sheath tumour
& Inflammatory fibroid polyp
Assessment of the degree of invasion of pT1 colorectal
cancer
pT1 cancers are those showing invasion through the
muscularis mucosae into the submucosa but not into the
muscularis propria.
Definition of invasion
We recommend the use of the WHO definition [23, 39]o f
an adenocarcinoma as an invasion of neoplastic cells
through the muscularis mucosae into the submucosa (VI-
A). The term intramucosal carcinoma should be substituted
by mucosal high-grade neoplasia according to the WHO
classification and the modified classification of neoplasia
recommended in the European Guidelines based on the
revised Vienna classification (see Table 1). We recognise
that this will not allow detailed comparison with Japanese
series where, contrary to the previous US and European
literature, a diagnosis of carcinoma can be made on cases of
neoplasia without submucosal invasion, or even on the
basis of marked intraepithelial atypia. The TNM classifica-
tion [40–42] allows carcinoma in situ (Tis) but this does not
improve on the revised Vienna classification and should not
be used. Please see Ref. [11] for details (VI-B).
Careful consideration should be given to the potential
for surgical overtreatment of misclassified early T1
cancers. Screening programmes require explicit criteria
for the diagnosis and staging of early adenocarcinoma
because unnecessary radical resection will raise the
m o r b i d i t ya n dm o r t a l i t yi nc o l o r e c t a lc a n c e rs c r e e n i n g
programmes. Please see annex [11] for further discussion
of this point. Post-operative mortality (within 30 days)
ranges between 0.6% and 4.4% in T1 cancers depending
on the population, age of patient and quality of services
available. Achieving the optimum balance between re-
moving all disease by resection and minimising harm is
very important.
Epithelial misplacement
Epithelial misplacement of adenomatous epithelium into
the submucosa of a polyp is a well-recognised phenomenon
[43]. It is commonly seen in prolapsing polyps in the
sigmoid colon. Experience suggests that this will be one of
the most difficult areas of pathological diagnostic practice
in FOBT screening. Sigmoid colonic polyps are particularly
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neoplastic changes present. When associated with epithelial
misplacement, the potential for misdiagnosis of these
lesions as early carcinoma become much greater. In cases
of epithelial misplacement, surrounding lamina propria and
haemosiderin-laden macrophages are found. Submucosal
mucinous lakes may be seen. These do not warrant an
immediate diagnosis of invasion and must be interpreted in
association with the surrounding features.
High-risk pT1 adenocarcinoma
pT1 tumours provide many difficulties in a screening
programme and the current evidence base for management
of these lesions is poor and based on symptomatic patients
[44–48] (V-B). With regard to the correlation between
clinical outcomes and tumour pathology, a clear indication
of an increased risk of residual disease, lymph-node
metastasis, haematogenous metastasis, and mortality was
observed after endoscopic polypectomy and subsequent
surgical resection of poorly differentiated tumours (i.e.
tumours with incomplete excision, poor grade of histo-
logical differentiation, venous and lymphatic invasion,
tumour budding). Some pathology features, such as
tumour budding and lymphatic and venous invasion
appeared as possible prognostic factors for increased risk
of lymph node metastasis but a clear guideline cannot be
drawn as this correlation was not statistically significant in
all studies. The available methods for substaging and
differentiation grading are shown below. The most
appropriate method depends on the morphology of the
lesion and depth of invasion, e.g. non-polypoid-Kikuchi
levels, and polypoid-Haggitt levels. In the future, more
quantitative measurements should be investigated as
suggested by the Japanese.
Substaging pT1
In pT1 tumours the frequency of lymph node metastasis in
tumours that involve the superficial, middle and deep thirds
of the submucosa, i.e. so-called Kikuchi levels sm1, sm2,
and sm3 (Fig. 1)[ 49, 50] has been reported to be 2%, 8%
and 23%, respectively [51].
In pedunculated polypoid lesions, Haggitt identified the
level of invasion into the stalk of the polyp (Fig. 2) as being
important in predicting outcome and found that level 4
invasion, in which the tumour extended beyond the stalk of
the polyp into the submucosa, but did not invade the
muscularis propria, was an adverse factor [52].
However, both the Kikuchi (for non-polypoid tumours)
and the Haggitt (for pedunculated tumours) systems may be
difficult to use in practice, especially if there is fragmen-
tation or suboptimal orientation of the tissue, and one study
found lymph node metastases in six of 24 Haggitt level 3
lesions. More recently Ueno et al. [53] have proposed use
of the depth (>2,000 μm) and width (>4,000 μm) of
invasion measured in microns beyond the muscularis
mucosae provides a more objective assessment of lymph
node metastatic potential 2.5% vs. 18.2% when submu-
cosal invasion width is < or ≥4,000 μm, respectively;
and 3.9% vs. 17.1%, when submucosal invasion depth
is < or ≥2,000 μm, respectively; and this approach has been
adopted in Japan. Each classification has advantages and
disadvantages.
Kikuchi cannot be used in the absence of muscularis
propria; Haggitt is not applicable in non-polypoid lesions,
and measurement depends on a recognisable submucosa
from which to measure. In view of the uncertainty and lack
of consensus, a firm evidence-based recommendation for
one method of assessing local invasion cannot yet be made.
At present we recommend the Kikuchi stage for non-
polypoid lesions and Haggitt for pedunculated lesions (VI-
C). All three approaches must be evaluated in further large
series from multiple programmes to derive adequately
evidence-based recommendations.
Tumour grade in pT1 lesions
Poorly differentiated carcinomas are identified by the
presence of either irregularly folded, distorted and often
small tubules or the lack of any tubular formation and
showing marked cytological pleomorphism. In the absence
of good evidence we recommend that a grade of poor
differentiation should be applied in a polyp cancer when
ANY area of the lesion is considered to show poor
differentiation. Poor differentiation should equate to the
WHO categories of poor and undifferentiated tumours [54].
The frequency should not exceed 20%. According to the
WHO classification [39], budding of the tumour cells at the
front of invasion should not influence grading of the
tumour. Please see Ref. [11] for details.
Lymphovascular invasion in pT1 adenocarcinomas
Definite invasion of endothelium-lined vascular spaces in
the submucosa is generally regarded as a significant risk for
lymph node or distant metastasis. Sometimes retraction
artefact around tumour aggregates can make assessment
uncertain, in which case this uncertainty should be recorded
and the observation should be interpreted in a multidisci-
plinary conference in the light of any other adverse
histological features. At the moment there are no consistent
data available on the additional use of immunohistochem-
istry, but this might be helpful in distinguishing retraction
artefacts from lymphatic (e.g. LEM D 2–40) or capillary
spread (e.g. CD 34).
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It is important to record whether the deep (basal) resection
margin is involved by invasive tumour (that may be a
reason for further surgery) and whether the lateral mucosal
resection margin is involved by carcinoma or the pre-
existing mucosal neoplasia (in which case a further local
excision may be attempted) (VI-B).
There has been considerable discussion and controversy
in the literature over what degree of clearance might be
regarded as acceptable in tumours that extend close to the
deep submucosal margin [55]. It is important that clearance
be measured and recorded in the report. All would agree
that a clearance of 0 mm, and most would agree that a
clearance of <1 mm is an indication for further therapy,
others would use <2 mm. Currently, we recommend that
clearance of 1 mm or less indicates margin involvement
(VI-B). However, this may be handled by removal of any
residual polyp endoscopically.
Tumour cell budding in pT1 adenocarcinomas
Tumour cell budding, i.e. the presence of small islands or
single infiltrating tumour cells at the front of tumour
invasion, has been described in the Japanese literature as
an unfavourable prognostic factor if present in a marked
degree [53, 56, 57]. Budding has been assessed either as
slight, moderate or marked; or as present/absent [58, 59].
However, its reproducibility has been criticised, the
diagnostic criteria vary [60] and the ability to predict
metastasis compared to the previously discussed factors is
unproven. Further research is needed in this area to identify
the optimum method and its reproducibility before tumour
cell budding can be recommended for routine use as an
indicator of metastasis. Please see Ref [11] for details.
Site
The site of origin of each specimen should be individually
identified by the clinician and provided to the pathologist
on the request form (VI-B). This should preferably include
both the segment of the bowel and the distance in cm from
the anus. The pathologist should record this information on
the proforma. This is important as the risk of lymph node
metastases from a T1 adenocarcinoma has been reported to
vary depending on the site of the lesion [61].
Specimen handling
Specimen handling is an important issue, as poor handling
and dissection procedures can impair diagnostic accuracy.
Fig. 2 Haggitt levels of inva-
sion in polypoid carcinomas
Fig. 1 Kikuchi levels of submucosal infiltration modified from Ref. [51]
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the specimen and ends with the histopathological diagnosis
and report. The need for a close relationship between
endoscopists and histopathologists is stressed.
Submission of specimens
It is recommended to place specimens in separate contain-
ers, one for each lesion, to avoid confusion about exact
location; if lesions are small, individual cassettes or multi-
cassettes can be used. Biopsies from the same lesion can be
placed in the same container. For endoscopic resections it is
helpful to pin out specimens by inserting pins through the
periphery of the specimen onto cork or thick paper. Too
much tension on the specimen could result in artificially
thinned lesions. Needles should not be placed directly
through a lesion but at the margin. Besides patient data, an
exact description on location should be provided (e.g. cms
from anocutanous line), as well as size and morphology
(stalked polyp, non-polypoid—Paris classification, etc.).
Additional information about central depression or focal
erosion or ulceration or coexistent chronic inflammatory
bowel disease can be useful. Endoscopic pictures can also
be submitted with the specimen(s).
Fixation
Fixation should be by buffered 10% formalin; this equals a
roughly 4% paraformaldehyde concentration, as formalin is
30–40% paraformaldehyde. Specimen(s) can shrink due to
formalin fixation, therefore measurements taken after
fixation can differ from those prior to fixation. Fixation in
alcohol is not recommended and if any other fixatives are
used a comparative study of size of adenomas after fixation
should be performed prior to use to avoid excessive
shrinkage of adenomas to avoid under treatment.
Dissection
The pathologist should verify the complete removal of
neoplastic lesions (clear margins) and the absence of submu-
cosal invasion in biopsy specimens. Currently, we recommend
that clearance of 1 mm or less indicates margin involvement
(VI-B). Cases of incomplete removal or uncertainty about
submucosal invasion should be highlighted in the pathology
report (VI-B). Lesion size should be given in millimetres. Size
should be carefully measured identifying the maximum
diameter of the adenomatous component as well as the distance
to the margin of excision(s) to within a millimeter (V-B).
Given the small dimensions of the submucosal layer,
infiltration into the submucosal level should be measured in
microns from the bottom line of the muscularis mucosae
(VI-B).
Polypoid lesions
Polyps must be sliced and totally embedded. Special
attention should be paid to the resection margin, which
should be identified and described (dot-like, broad, stalked
etc.) and either dissected tangentially into an extra cassette
or sliced in a way that allows complete assessment.
Mucosal excisions
Mucosal excisions need to be pinned out on a cork board
or on another suitable type of material, fixed, described
and dissected allowing the identification of involvement
of the deep and lateral surgical margins. Particular
attention should be paid to any areas of ulceration or
induration for signs of invasion. Inking margins is
recommended.
Piecemeal removal
If it is possible to reconstruct a lesion removed piecemeal it
may be helpful but this is not commonly the case. It is good
practice to embed the entire lesion to allow exclusion of
invasive malignancy. Occasionally, whole embedding will
not be possible.
Sectioning and levels
Three or more levels should be cut through each block and
stained with haematoxylin and eosin.
Surgically removed lesions
Classification
The staging of colorectal cancer can be undertaken by a
number of different systems. The two used in Europe are
TNM and the older Dukes classification. Originally the
Dukes classification system placed patients into one of
three categories (stages A, B, C) (see Table 2). This system
Table 2 Modified Dukes stage
Dukes A Tumour penetrates into but not through the muscularis
propria (the muscular layer) of the bowel wall
Dukes B Tumour penetrates into and through the muscularis propria
of the bowel wall but does not involve lymph nodes
Dukes C C1: There is pathological evidence of adenocarcinoma in
one or more lymph nodes but not the highest node
C2: There is pathological evidence of adenocarcinoma in
the lymph node at the high surgical tie
Stage D Tumour has spread to other organs (such as the liver, lung
or bone)
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C1 and C2 and the addition of a fourth stage (D). More
recently, the Union Internationale Contra le Cancer (UICC)
and the American Joint Committee on Cancer (AJCC) has
introduced the TNM staging system, that places patients
into one of four stages (stages I–IV). TNM is superior to
Dukes because of the greater information it yields, but there
are currently major issues due to the periodic reclassifica-
tion of this system that can lead to stage migration. TNM
has a number of versions, so the version used should be
noted in brackets (e.g. v5, v6, v7). Tables 3, 4 and 5 permit
comparison of the most recent versions, 5, 6 and 7 [40–42].
However, there are differences between the versions,
particularly regarding the notes on T and N classification.
There is also variation between countries as to the TNM
classification used. For example, TNM 5 is recommended
in the UK, Holland, Belgium and Denmark and is growing
in popularity in other countries.
In the USA, version 7 is used. TNM 7 appears to be more
subjective than TNM 5 due to the notes on N classification
andthe category N1c,promotingstage migration fromIItoIII
[62–64]. National results should be reported with the version
of TNM used in a given country (VI-B).
Practical issues
High-quality reporting of colorectal cancer is very impor-
tant both to the clinicians treating the patients and to the
cancer registry. The introduction of a ‘minimum’ data
proforma template allows more complete reporting com-
pared with interpretation of free text reports by medical
staff [65–72]. All biopsies and lesions identified in the
screening programme and the subsequent resection speci-
mens should be reported on a paper or electronic proforma
(II-B) in a timely manner and in a minimum of 90% of all
cases. The proforma should be sent to the referring
physician, the relevant cancer registry and the screening
programme (VI-B).
Dissection should be according to national guidelines
such as those for the UK; Royal College of Pathologists
Table 3 TNM classification of tumours of the colon and rectum
Clinical classification 5th edition (1997) 6th edition (2002) 7th edition (2009)
T—primary tumour
TX Primary tumour cannot be assessed + + +
T0 No evidence of primary tumour + + +
Tis
1 Carcinoma in situ: intraepithelial or invasion of lamina propria + + +
T1 Tumour invades submucosa + + +
T2 Tumour invades muscularis propria + + +
T3 Tumour invades through muscularis propria into subserosa or into non-
peritonealised pericolic or perirectal tissues
+++
T4
2,3 Tumour directly invades into other organs or structures and/or
perforates visceral peritoneum
+++
T4a Perforates visceral peritoneum ––+
T4b Directly invades other organ or structures ––+
N—regional lymph nodes
NX Regional lymph nodes cannot be assessed + + +
N0 No regional lymph node metastasis + + +
N1 Metastasis in 1 to 3 regional lymph nodes + + +
N1a 1 node ––+
N1b 2–3 nodes ––+
N1c Satellites
4 in subserosa, without regional nodes ––+
N2 Metastasis in 4 or more regional lymph nodes + + +
N2a 4–6 nodes ––+
N2b 7 or more nodes ––+
M—distant metastasis
MX Distant metastasis cannot be assessed + + –
M0 No distant metastasis + + +
M1 Distant metastasis + + +
M1a Metastasis confined to one organ (liver, lung, ovary, non-regional
lymph node(s))
––+
M1b Metastasis in more than one organ or the peritoneum ––+
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[76], the Scottish clinical guidelines [77], the Dutch
guidelines [78, 79], the German guidelines [80] or the
Italian guidelines [81]. For examples of these guidelines see
the list of websites in Appendix 4 of the full guideline
document [9]. If national guidelines do not exist they
should be created or adopted from elsewhere (VI-B). An
additional free text written report is optional, but needs to
include all of the data required in the proforma (VI-B).
Pathologists need access to a high-quality, binocular
microscope with at least the following objectives: 5×, 10×,
20× and 40× and that fulfils national guidelines such as
those of the Sector Committee for Pathology and Neuropa-
thology of the German Accreditation Body [82]
A computer is required for identifying previous material
from a given patient and for filling in proformas electronically
and online if secure online services are available. Adequate
timemustbeavailablefordissection,reporting,andattendance
at meetings of the screening team and the colorectal cancer
multidisciplinary team (VI-B). Time and funding are required
for pathologists to attend national meetings on the screening
programme and continued training in histopathology of
colorectal neoplasia. Pathologists should attend one refresher
training course every year on the pathology of colorectal
neoplasia to maintain quality (VI-B).
Standards and quality indicators
There should be good communication between members of
the screening team with agreed terminology, regular meetings
and clinical discussions (VI-B).
An external quality assurance programme should be put
in place, specifying a minimum of two slide circulations per
year of an adequate number of slides (VI-B). This may be
via clusters or cells of pathologists using glass slides, or can
be electronic using images or virtual slides [83] distributed
via DVD or the web (see http://www.virtualpathology.leeds.
ac.uk). There should be external oversight of such
programmes. In the absence of evidence-based guidelines
we recommend that pathologists reporting in a colonoscopy
programme should not report high-grade neoplasia in more
than 5% of lesions and those in an FOBT programme in not
more than 10% of lesions (VI-B).
The pathologists reporting in the programme must meet
their national criteria for safety in reporting colorectal
cancer (VI-B). Departments and pathologists taking part in
screening programmes should audit their own reporting
practices for key features, including the number of lymph
nodes retrieved, the frequency of circumferential resection
margin involvement (CRM) and the frequency of high-risk
features such as extramural vascular invasion and peritoneal
Stage Stage grouping 5th Edition (1997) 6th Edition (2002) 7th Edition (2009)
TNM
Stage 0 Tis N0 M0 + + +
Stage I T1,T2 N0 M0 + + +
Stage II T3,T4 N0 M0 ––+
Stage IIA T3 N0 M0 + + +
Stage IIB T4 N0 M0 + + –
Stage IIB T4a N0 M0 ––+
Stage IIC T4b N0 M0 ––+
Stage III Any T N1, N2 M0 ––+
Stage IIIA T1,T2 N1 M0 + + +
Stage IIIA T1,T2 N1c M0 ––+
Stage IIIA T1 N2a M0 ––+
Stage IIIB T3,T4 N1 M0 + + –
Stage IIIB T3,T4a N1/N1c M0 ––+
Stage IIIB T2,T3 N2a M0 ––+
Stage IIIB T1,T2 N2b M0 ––+
Stage IIIC Any T N2 M0 + + –
Stage IIIC T4a N2a M0 ––+
Stage IIIC T3,T4a N2b M0 ––+
Stage IIIC T4b N1, N2 M0 ––+
Stage IV Any T Any N M1 + + –
Stage IVA Any T Any N M1a ––+
Stage IVB Any T Any N M1b ––+
Table 4 TNM stage grouping
of tumors
T tumour, N node, M metastasis
Virchows Arch (2011) 458:1–19 13invasion reported (VI-B). In the UK, national standards
suggest that the number of nodes retrieved should be above
a median of 12, CRM positivity in rectal cancer should be
below 15%, extramural vascular invasion reported in more
than 25%, and peritoneal invasion in more than 20%. The
laboratory must be able to demonstrate participation in a
laboratory technical external quality assurance programme,
such as Clinical Pathology Accreditation UK (http://www.
cpa-uk.co.uk/), the ISO/IEC accreditation developed by the
Sector Committee for Pathology and Neuropathology of the
German Accreditation Body (http://www.dakks.de/,s e e
also Ref. [84]), or other national standards (VI-C).
Data collection and monitoring
Lesions reported in the screening programme should be
reported by proforma (II-B) or structured reporting, and the
Table 5 Notes
No. Notes
5th edition 6th edition 7th edition
1 Tis includes cancer cells confined within the glandular basement membrane (intraepithelial) or lamina propria (intramucosal) with no
extension through muscularis mucosae into the submucosa. Note: the authors of the European Guidelines for quality assurance in
pathology in CRC screening and diagnosis recommend not using this category. Respective lesions should be reported as mucosal
high-grade neoplasia, see above (“Grading of neoplasia”)
2 Direct invasion in T4 includes invasion of other segments of the colon or rectum by way of
the serosa, e.g. invasion of sigmoid colon by a carcinoma of the cecum
Direct invasion in T4b includes invasion of
other organs or segments of the colon or
rectum by way of the serosa, as confirmed
on microscopic examination, or for
tumours in a retroperitoneal or
subperitoneal location, direct invasion of
other organs or structures by virtue of
extension beyond the muscularis propria
3 Tumour that is adherent to other organs or
structures, macroscopically, is classified
T4. However, if no tumour is present in
the adhesion, microscopically, the
classification should be pT3
Tumour that is adherent to other organs or
structures, macroscopically, is classified
cT4b. However, if no tumour is present in
the adhesion, microscopically, the
classification should be pT1–T3,
depending on the anatomical depth of
wall invasion
4 A tumour nodule greater than 3 mm in
diameter in perirectal or pericolic adipose
tissue without histological evidence of a
residual lymph node in the nodule is
classified as regional lymph node
metastasis. However, a tumour nodule up
to 3 mm in diameter is classified in the T
category as discontinuous extension i.e.
T3.
A tumour nodule in the pericolic/perirectal
adipose tissue without histological
evidence of a residual lymph node in the
nodule is classified in the pN category as
a regional lymph node metastasis if the
nodule has the form and smooth contour
of a lymph node. If the nodule has an
irregular contour it should be classified in
the T category and also coded as V1
(microscopic venous invasion) or V2, if it
was grossly evident, because there is a
strong likelihood that it represents venous
invasion
Tumour deposits (satellites), i.e.
macroscopic or microscopic nests or
nodules, in the pericolorectal adipose
tissue’s lymph drainage area of a primary
carcinoma without histological evidence
of residual lymph node in the nodule,
may represent discontinuous spread,
venous invasion with extra-vascular
spread (V1/2) or a totally replaced lymph
node (N1/2). If such deposits are
observed with lesions that would
otherwise be classified as T1 or T2, then
the T classification is not changed, but the
nodule is recorded as N1c. If a nodule is
considered by the pathologist to be a
totally replaced lymph node (generally
having a smooth contour), it should be
recorded as a positive lymph node and not
as a satellite, and each nodule should be
counted separately as a lymph node in the
final pN determination. (Note of the
authors of the European Guidelines for
quality assurance in pathology in CRC
screening and diagnosis: introduction of
N1c category leads to stage shift from II
to III for some tumours)
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tumour registries. This will include all lesions identified
and the subsequent resection specimen. This should occur
in a minimum of 90% of all cases (VI-B).
Studies have shown discrepancy between the histopathol-
ogy of biopsies and total removal by polypectomy, EMR and
surgical specimens.Colorectalcancerwas detectedinsurgical
specimens inover20% ofbiopsies diagnosed withhigh-grade
neoplasia [85]. Sub-mucosal invasion was detected in
surgical specimens in over 25% of cases with mucosal
neoplasia [22]. Therefore, the correlation between histolog-
ical diagnosis of biopsies and resections should be reported.
Any lack of correlation should be discussed by the
multidisciplinary team and the results of this discussion
should be documented (III-B).
Pathologists must ensure that their proformas are
received by the screening programme coordinators or a
cancer registry for the purposes of clinical management,
audit and quality assurance (VI-B).
Results from the key indicators of quality should be
returned for analysis to the funding body: either the Health
Authority or the national screening programme’s offices
(VI-B).
Statistics should include the frequency of colorectal cancer
and the distribution of TNM stages and version used; as well
as the distribution of the type of lesion, size, location,
frequency of grades of dysplasia and villousness (villous,
tubulo-villous or tubular) and presence of non-neoplastic
lesions (VI-B).
Images
A selection of images and digital slides showing the
histopathology of lesions commonly detected in screening
programmes, as well as some images illustrating pitfalls in
histopathologic interpretation is provided in the internet at
http://www.virtualpathology.leeds.ac.uk (go to: “European
Guidelines for quality assurance in pathology in colorectal
cancer screening and diagnosis—Imaging library”). The
site has been created to establish an initial, quality-assured
repository for images illustrating the chapter on pathology
in the first guideline edition [10]. The images are provided
here for reference and have been reviewed by pathologists
from at least three European countries. We encourage
colleagues to submit further images which they feel could
be instructive or otherwise useful in illustrating or further
developing the European Guidelines.
We also aim to extend the scope of this site in the future
to promote pan-European and international collaboration
in training and in expanding the evidence base for
further advances in colorectal cancer screening and
diagnosis.
Conclusions and recommendations
Ina state-of-the-artprocess,wideconsensushasbeenachieved
on the following evidence-based recommendations for quality
assurance of pathology in colorectal cancer screening and
diagnosis. In light of the experience with similar guidelines for
breast and cervical cancer screening in the EU, the future
availability of this reference document has the potential to
improve multidisciplinary management of colorectal cancer
detected within and outside the setting of screening pro-
grammes. The availability of a uniform classification for
reporting lesions detected in screening programmes across
Europe also has the potential to improve international
collaboration and exchange of experience in improving the
quality and effectiveness of colorectal cancer care.
1. Due to the improved diagnostic reproducibility of the
revised Vienna classification use of this classification
in a format modified for lesions detected in screening
is recommended to ensure consistent international
communication and comparison of histopathology of
biopsies and resection specimens (IV-B). Only two
grades of colorectal neoplasia (low grade and high
grade) should be used, to minimise intraobserver and
interobserver error (V-B). The terms intramucosal
adenocarcinoma or in-situ carcinoma should not be
used (VI-B).
2. The World Health Organisation (WHO) definition of
colorectal adenocarcinoma should be used: “an invasion
of neoplastic cells through the muscularis mucosae into
the submucosa” (VI-A).
3. Adenocarcinomas should be reported according to the
tumour, node, metastasis (TNM) classification. The
version of TNM to be used should be decided
nationally and should be stated e.g. pT1 pN0 pMX
(Version 5) or pT4 pN2 pM1 (Version 7). These can
be further abbreviated to pT1N0MX (v5) or to
pT4N2M1 (v7) (VI-B).
4. The WHO classification of adenomas into tubular,
tubulo-villous and villous should be used (VI-A).
5. Due to the increased risk of colorectal cancer
associated with flat and/or depressed lesions they
should be reported as non-polypoid lesions (III) and
further classified by the Paris classification (V-B).
6. The pathologist should verify the complete removal of
neoplastic lesions (clear margins) and the absence of
submucosal invasion in biopsy specimens. Currently we
recommend that clearance of 1 mm or less indicates
margin involvement (VI-B). Cases of incomplete remov-
al or uncertainty about submucosal invasion should be
highlighted in the pathology report (VI-B).
7. Substaging of T1 cancers should be performed to
determine the risk of residual disease. Consideration
Virchows Arch (2011) 458:1–19 15should be given to the appropriate method, which may
vary depending on the morphology of the lesion
(Kikuchi/Haggitt or measurement). For non-polypoid
lesions the Kikuchi stage and for pedunculated lesions
Haggitt are currently recommended (VI-C). High-risk
features for residual disease such as lack of margin
clearance (≤1 mm), poor differentiation and lymphatic
and vascular invasion should be reported (V-B). The
multidisciplinary team should be consulted on wheth-
er or not surgical resection of pT1 adenocarcinoma is
recommended; if surgical resection is recommended,
consideration should be given to obtaining an opinion
from a second histopathologist as variation exists in
evaluating high-risk features (VI-A).
8. The size of lesions should be carefully measured by
the pathologist to the nearest mm on the haematoxylin
and eosin slide, or on the fixed specimen when the
largest dimension of the lesion cannot be reliably
measured on the slide. Endoscopy measurements are
less accurate and should only be used when strictly
necessary, e.g. if the lesion is fragmented (III-B).
Given the small dimensions of the submucosal layer,
infiltration into the submucosal level should be
measured in microns from the bottom line of the
muscularis mucosae (VI-B).
9. Programmes should have a policy on the methodology
of, and should regularly monitor the accuracy of size
measurements of endoscopically removed lesions. De-
viation between the actual size and the measurements of
pathologists and endoscopists should be minimised.
Management decisions which depend on lesion size
should take into account potential inaccuracy in the size
measurement. The multidisciplinary team should con-
sider deviating from the recommended size categories in
treatment and surveillance algorithms, if the review of a
case indicates that there is sufficient reason to doubt the
accuracy of the measurement. Such cases should be
captured as an auditable outcome (VI-B).
10. Hyperplastic polyps are non-neoplastic and their
complete removal is optional. All other lesions in the
serrated pathway should be excised and serrated
lesions with neoplasia should be followed up (sur-
veillance) as if they were adenomas (VI-C).
11. All biopsies and lesions identified in the screening
programme and the subsequent resection specimen
should be reported on a proforma (IV-B) in a timely
manner and in a minimum of 90% of all cases. The
proforma should be sent to the referring physician, the
relevant cancer registry and the screening programme
(VI-B).
12. Dissection of all specimens should be according to
national guidelines. If national guidelines do not exist
they should be created or adopted from elsewhere. An
additional free text written report is optional, but must
include all of the data required in the proforma (VI-B).
13. The correlation between histological diagnosis of
biopsy and surgical specimens should be reported.
Any lack of correlation should be discussed by the
multidisciplinary team, and the results of this dis-
cussion should be documented (III-B).
14. Pathologists must ensure that their proformas are received
by the screening programme coordinators or a cancer
registry for the purposes of clinical management, audit
and quality assurance. Results from the key indicators of
quality should be returned to the funding body: either the
Health Authority or the national screening programmes’
offices for analysis (VI-B).
15. Statistics should include the frequency of colorectal
cancer and the distribution of TNM stages and version
used, as well as the distribution of the type of lesion,
size, location, frequency of grades of neoplasia and
villousness (villous, tubulo-villous or tubular) and
presence of non-neoplastic lesions (VI-B).
16. There should be good communication between the
members of the screening team with agreed terminol-
ogy, regular meetings and clinical discussions (VI-B).
17. Pathologists taking part in a colorectal cancer screen-
ing programme must participate regularly in multidis-
ciplinary team meetings, and twice a year in an
external quality assurance programme that has exter-
nal oversight of the results (VI-B).
18. Departments and individual pathologists should audit
their own reporting practices for key features (VI-B).
19. Pathologists reporting in a colorectal cancer screening
programme must meet their national criteria for safety
in reporting colorectal cancer (VI-B).
20. Departments and pathologists taking part in screening
programmes should audit the number of lymph nodes
retrieved, the frequency of circumferential resection
margin involvement and the frequency of high-risk
features such as extramural vascular invasion, tumour
perforation and peritoneal invasion reported (VI-B).
21. Pathologists reporting in a colonoscopy screening
programme should not report high-grade neoplasia in
more than 5% of lesions and those in an Faecal Occult
Blood Test programme in not more than 10% of
lesions (VI-B).
22. Pathologists should attend one refresher training
course every year on the pathology of colorectal
neoplasia to maintain quality (VI-B).
23. Laboratories participating in a screening programme
must be able to demonstrate participation in a laboratory
technical external quality assurance programme and
hold external accreditation for their services (VI-C).
Further detailed information can be found in Ref. [11].
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